We performed post hoc analyses on the utility of pretherapeutic and early interim 68Ga-
DOTATOC PET tumor uptake and volumetric parameters and a recently proposed …

To meet the increasing demand for PRRT in the treatment of patients with inoperable/
disseminated well-differentiated neuroendocrine tumors (NETs) and to guide optimization …

The aim of this study was to determine whether quantitative PET parameters on baseline
68Ga-DOTATATE PET/CT and interim PET (iPET) performed before the second cycle of …

Purpose [177 Lu] DOTATATE prolongs progression free survival (PFS) in metastatic
neuroendocrine tumours (NETs). However, objective response rate is low. This, coupled …

Background Our goal is to quantitatively compare radiotracer biodistributions within tumors
and major normal organs on pretherapy 68 Ga-DOTATATE PET to post-therapy 177 Lu …

We aimed to evaluate 68Ga-DOTATATE PET/CT for the early prediction of time to
progression and clinical outcome after a first cycle of peptide receptor radionuclide treatment …

Purpose Pretreatment predictions of absorbed doses can be especially valuable for patient
selection and dosimetry-guided individualization of radiopharmaceutical therapy. Our goal …

This study aimed to assess the clinical impact of 68Ga-DOTATATE and 18F-FDG with
respect to the management plan and to evaluate the prognostic value of both tracers …

Discordance between histopathologic grading and dual-tracer PET/CT (68Ga-DOTATATE
and 18F-FDG) findings in neuroendocrine tumors (NETs), though not typical, can be …

Background Peptide receptor radionuclide therapy (PRRT) is one of the most effective
therapeutic options for the treatment of metastatic, well-differentiated neuroendocrine tumors …